November 2013
Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 Years
December 5th 2013A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.
TRINOVA-1 Trial: Promise for Trebananib in Ovarian Cancer
December 4th 2013Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.
Additional OS and PFS Benefits With Aflibercept in Post-Hoc VELOUR Analysis
December 3rd 2013A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with mCRC.
Model Emerges for Targeting Oncogenes in NSCLC
December 3rd 2013Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.
